Hospital trial aims to stop deadly c. diff before it starts
NCT ID NCT05389904
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests a prevention bundle for hospital patients who carry C. difficile bacteria but have no symptoms. The bundle includes enhanced room cleaning and special precautions. Researchers hope to prevent these carriers from developing active infections and spreading the bacteria to others. The study enrolls 300 patients in ICU or oncology units.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- prevention bundle (enhanced cleaning, precautions)
- What this could lead to
- If it works, this could reduce hospital-acquired C. difficile infections and deaths by catching carriers early.
- What could go wrong
- This is a small, early-stage trial (300 patients) testing a bundle of measures, not a new drug. Results may not apply to all hospitals or patient groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2022
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients admitted to ICU or Oncology units and identified to carry C. Difficile via VRE swab Exclusion Criteria: * Patients not identified as carriers of C. difficile and patients not admitted to ICU or oncology units
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for C. difficile are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States